keyword
MENU ▼
Read by QxMD icon Read
search

paliperidone

keyword
https://www.readbyqxmd.com/read/29776316/a-systematic-review-and-combined-analysis-of-therapeutic-drug-monitoring-studies-for-oral-paliperidone
#1
Georgios Schoretsanitis, Edoardo Spina, Christoph Hiemke, Jose de Leon
This article includes a combined analysis of therapeutic drug monitoring (TDM) studies and a review of the marketer's data on pharmacological mechanisms. Areas covered: An article search led to the inclusion of 21 paliperidone studies in the systematic review plus 2 case reports. Paliperidone clearance was calculated from: 1) steady-state studies using concentration/dose (C/D) ratios, and 2) single-dose studies describing 24-hour area under the curve calculations. The marketed extended-release formulation has 28% bioavailability...
May 18, 2018: Expert Review of Clinical Pharmacology
https://www.readbyqxmd.com/read/29766576/predictive-factors-of-overall-functioning-improvement-in-patients-with-chronic-schizophrenia-and-schizoaffective-disorder-treated-with-paliperidone-palmitate-and-aripiprazole-monohydrate
#2
Paolo Girardi, Antonio Del Casale, Chiara Rapinesi, Georgios D Kotzalidis, Francesca Splendori, Claudio Verzura, Giada Trovini, Serena Sorice, Dario Carrus, Iginia Mancinelli, Anna Comparelli, Sergio De Filippis, Antonio Francomano, Andrea Ballerini, Andrea Marcellusi, Francesco S Mennini, Giuseppe Ducci, Gabriele Sani, Maurizio Pompili, Roberto Brugnoli
BACKGROUND: Long-acting injectable (LAI) antipsychotics can improve medication adherence and reduce hospitalisation rates compared with oral treatments. Paliperidone palmitate (PAL) and aripiprazole monohydrate (ARI) LAI treatments were associated with improvements in global functioning in patients with schizophrenia. OBJECTIVE: The objective of this study was to assess the predictive factors of better overall functioning in patients with chronic schizophrenia and schizoaffective disorder treated with PAL and ARI...
May 15, 2018: Human Psychopharmacology
https://www.readbyqxmd.com/read/29764266/impact-of-paliperidone-palmitate-one-month-formulation-on-relapse-prevention-in-patients-with-schizophrenia-a-post-hoc-analysis-of-a-one-year-open-label-study-stratified-by-medication-adherence
#3
Tianmei Si, Nan Li, Huafei Lu, Shangli Cai, Jianmin Zhuo, Christoph U Correll, Lili Zhang, Yu Feng
BACKGROUND: Limited data are available to help identify patients with schizophrenia who are most likely to benefit from long-acting injectable antipsychotics. AIM: The purpose of this study was to investigate the efficacy of long-acting injectable antipsychotic paliperidone palmitate one-month formulation for preventing relapses, factors influencing time to first relapse, and the effect of different antipsychotic adherence levels on time to first relapse in Chinese patients with schizophrenia...
May 1, 2018: Journal of Psychopharmacology
https://www.readbyqxmd.com/read/29758999/movement-disorders-associated-with-antipsychotic-medication-in-people-with-schizophrenia-an-overview-of-cochrane-reviews-and-meta-analysis
#4
Davide Martino, Vikram Karnik, Sydney Osland, Thomas R E Barnes, Tamara M Pringsheim
Movement disorders associated with antipsychotic medications are relatively common, stigmatising, and potentially disabling. Their prevalence in people with psychosis who are prescribed second-generation antipsychotics (SGAs) is uncertain, as is their level of recognition by clinicinas. We conducted meta-analyses of randomised controlled trials included in the Cochrane Database of Systematic Reviews on schizophrenia and schizophrenia-like psychoses to estimate the prevalence of new-onset dystonia, akathisia, parkinsonism, and tremor with SGAs (amisulpride, asenapine, aripiprazole, clozapine, olanzapine, paliperidone, quetiapine, risperidone, L-sulpiride, and ziprasidone) approved in Canada and the UK, comparing them with haloperidol and chlorpromazine...
January 1, 2018: Canadian Journal of Psychiatry. Revue Canadienne de Psychiatrie
https://www.readbyqxmd.com/read/29756288/mixed-states-in-bipolar-and-major-depressive-disorders-systematic-review-and-quality-appraisal-of-guidelines
#5
REVIEW
N Verdolini, D Hidalgo-Mazzei, A Murru, I Pacchiarotti, L Samalin, A H Young, E Vieta, A F Carvalho
OBJECTIVE: This systematic review provided a critical synthesis and a comprehensive overview of guidelines on the treatment of mixed states. METHOD: The MEDLINE/PubMed and EMBASE databases were systematically searched from inception to March 21st, 2018. International guidelines covering the treatment of mixed episodes, manic/hypomanic, or depressive episodes with mixed features were considered for inclusion. A methodological quality assessment was conducted with the Appraisal of Guidelines for Research and Evaluation-AGREE II...
May 13, 2018: Acta Psychiatrica Scandinavica
https://www.readbyqxmd.com/read/29746335/case-report-paliperidone-palmitate-but-not-aripiprazole-as-a-possible-risk-factor-for-pulmonary-embolism
#6
Isabelle Michaud, Pierre Landry
No abstract text is available yet for this article.
May 8, 2018: Journal of Clinical Psychopharmacology
https://www.readbyqxmd.com/read/29734130/baseline-results-from-the-european-non-interventional-antipsychotic-long-acting-injection-in-schizophrenia-alto-study
#7
Pierre-Michel Llorca, Julio Bobes, W Wolfgang Fleischhacker, Stephan Heres, Nicholas Moore, Nawal Bent-Ennakhil, Christophe Sapin, Jean-Yves Loze, Anna-Greta Nylander, Maxine X Patel
BACKGROUND: The Antipsychotic Long-acTing injection in schizOphrenia (ALTO) study was a non-interventional study across several European countries examining prescription of long-acting injectable (LAI) antipsychotics to identify sociodemographic and clinical characteristics of patients receiving and physicians prescribing LAIs. ALTO was also the first large-scale study in Europe to report on the use of both first- or second-generation antipsychotic (FGA- or SGA-) LAIs. METHODS: Patients with schizophrenia receiving a FGA- or SGA-LAI were enrolled between June 2013 and July 2014 and categorized as incident or prevalent users...
May 4, 2018: European Psychiatry: the Journal of the Association of European Psychiatrists
https://www.readbyqxmd.com/read/29731633/impact-of-time-of-initiation-of-once-monthly-paliperidone-palmitate-in-hospitalized-asian-patients-with-acute-exacerbation-of-schizophrenia-a-post-hoc-analysis-from-the-prevail-study
#8
Huafang Li, Yan Li, Yu Feng, Jianmin Zhuo, Ibrahim Turkoz, Maju Mathews, Wilson Tan
Purpose: To evaluate the differences in efficacy and safety outcomes in acute exacerbating schizophrenia patients between 2 subgroups (≤1 week and >1 week), differing in time interval from hospitalization to time of initiation of once-monthly paliperidone palmitate. Patients and methods: PREVAIL was a multicenter, single-arm, open-label, prospective Phase IV study in hospitalized Asian patients (either sex, aged 18-65 years) diagnosed with schizophrenia ( Diagnostic and Statistical Manual of Mental Disorders , Fourth Edition)...
2018: Neuropsychiatric Disease and Treatment
https://www.readbyqxmd.com/read/29722547/adherence-and-economic-impact-of-paliperidone-palmitate-versus-oral-atypical-antipsychotics-in-a-medicare-population
#9
Kruti Joshi, Erik Muser, Yihua Xu, Phil Schwab, Manasi Datar, Brandon Suehs
AIM: To compare adherence, healthcare utilization and costs among real world, Medicare-eligible patients with schizophrenia using long-acting injectable paliperidone palmitate (PP) versus oral atypical antipsychotics. Patients & methods: Historical cohort study used Medicare Advantage claims data. Inverse probability of treatment weighting was applied to adjust for baseline differences. 12-month adherence, healthcare utilization and costs were compared. RESULTS: Patients using PP were more adherent (proportion of days covered ≥0...
May 3, 2018: Journal of Comparative Effectiveness Research
https://www.readbyqxmd.com/read/29715183/c-fos-expression-in-the-hypothalamic-paraventricular-nucleus-after-a-single-treatment-with-a-typical-haloperidol-and-nine-atypical-antipsychotics-a-pilot-study
#10
Alexander Kiss
OBJECTIVE: The aim of the present study was to find out whether acute effect of different doses of selected antipsychotics including aripiprazole (ARI), amisulpride (AMI), asenapine (ASE), haloperidol (HAL), clozapine (CLO), risperidone (RIS), quetiapine (QUE), olanzapine (OLA), ziprasidone (ZIP), and paliperidone (PAL) may have a stimulatory impact on the c-Fos expression in the hypothalamic paraventricular nucleus (PVN) neurons. METHODS: Adult male Wistar rats weighing 280-300 g were used...
April 1, 2018: Endocrine Regulations
https://www.readbyqxmd.com/read/29713451/effectiveness-of-paliperidone-long-acting-injection-in-clinical-practice
#11
Paul Nicholas Deslandes, Elan Haf Ward, Kathryn Norris, Robert David Sewell
Background: The efficacy of the long-acting injectable formulation of the antipsychotic paliperidone (paliperidone palmitate) has been investigated in randomized controlled trials. Due to the nature of study designs, these may not be representative of usual clinical practice. The aim of this study was to assess the clinical effectiveness of the long-acting injectable antipsychotic paliperidone palmitate using treatment continuation at 1 year as an outcome. Methods: Patients were initiated on paliperidone palmitate prior to December 2014 in a single health board in Wales (UK)...
May 2018: Therapeutic Advances in Psychopharmacology
https://www.readbyqxmd.com/read/29713100/do-long-acting-injectable-antipsychotics-prevent-or-delay-hospital-readmission
#12
Thomas J Maestri, Lisa M Mican, Heather Rozea, Jamie C Barner
Introduction: Long-acting injectable (LAI) antipsychotics were developed as a way to decrease pill burden and simplify medication regimens by allowing less frequent administration to assist with medication adherence. Methods: The purpose of this study was to determine whether LAI antipsychotics prevent or delay hospital readmission in patients with a known history of medication non-adherence. The study is a retrospective evaluation of 240 men and women 18-65 years of age diagnosed with bipolar disorder, schizophrenia, or schizoaffective disorder discharged from an inpatient state hospital over a 2 year period of time on a LAI antipsychotic (fluphenazine LAI, haloperidol LAI, risperidone LAI or paliperidone LAI) or oral antipsychotic...
March 13, 2018: Psychopharmacology Bulletin
https://www.readbyqxmd.com/read/29707876/maintenance-dose-conversion-between-oral-risperidone-and-paliperidone-palmitate-1-month-practical-guidance-based-on-pharmacokinetic-simulations
#13
Alberto Russu, Jennifer Kern Sliwa, Paulien Ravenstijn, Arun Singh, Maju Mathews, Edward Kim, Srihari Gopal
AIM: We assessed the dosage strengths of paliperidone palmitate 1-month (PP1M) long-acting injectable resulting in similar steady-state (SS) exposures to the dosage strengths of oral risperidone using pharmacokinetic (PK) simulations. METHODS: Population PK simulations of SS PK were performed using the PK models of oral risperidone and PP1M. The concentrations of active moiety (risperidone + paliperidone) from risperidone were compared to paliperidone concentrations resulting from PP1M administration...
April 30, 2018: International Journal of Clinical Practice
https://www.readbyqxmd.com/read/29694244/cost-effectiveness-of-long-acting-injectable-aripiprazole-once-monthly-400-mg-in-bipolar-i-disorder-in-the-usa
#14
Margarida Augusto, Mallik Greene, Maëlys Touya, Samantha Min Sweeney, Heidi Waters
AIM: To evaluate the cost-effectiveness of aripiprazole once-monthly 400/300 mg (AOM 400) in maintenance monotherapy treatment of bipolar I disorder (BP-I). METHODS: A de novo lifetime Markov model was developed for BP-I using available data for AOM 400 and relevant comparators. Base-case analysis considered costs and outcomes from the US payer perspective. RESULTS: The cost per quality-adjusted life year gained with AOM 400 versus comparators ranged from US$2007 versus oral asenapine to dominance (i...
April 25, 2018: Journal of Comparative Effectiveness Research
https://www.readbyqxmd.com/read/29694243/budget-impact-analysis-of-long-acting-injectable-aripiprazole-once-monthly-400-mg-in-bipolar-i-disorder-in-the-usa
#15
Margarida Augusto, Mallik Greene, Maëlys Touya, Samantha Min Sweeney, Heidi Waters
AIM: To estimate the budget impact (BI) of introducing aripiprazole once-monthly 400 mg/300 mg (AOM 400) in the maintenance monotherapy treatment of bipolar I disorder versus long-acting injectables, oral antipsychotics and best supportive care. METHODS: A BI model was developed from a US-payer perspective using treatment-related, hospitalization and adverse event management cost estimates for a hypothetical 1,000,000-member health plan over a 5-year period. RESULTS: Market share of AOM 400 was predicted to increase from 0...
April 25, 2018: Journal of Comparative Effectiveness Research
https://www.readbyqxmd.com/read/29680794/risperidone-associated-sinus-tachycardia-potentiated-by-paliperidone-palmitate-in-a-patient-with-no-prior-cardiovascular-disease-role-of-risperidone-related-autonomic-instability
#16
Alain Bruno Tagne Nouemssi
Risperidone and paliperidone palmitate are two antipsychotic drugs well tolerated in the management of schizophrenia and other psychiatric conditions. There have been few reports of tachycardia induced by either drugs. Here, we report on a 21-year-old man, with a history of schizophrenia, and who developed persistent sinus tachycardia after he was restarted on risperidone, which later worsened after administration of paliperidone palmitate for long-term management. He had no cardiovascular risk factors other than obesity, and a prior well-tolerated risperidone treatment...
April 21, 2018: BMJ Case Reports
https://www.readbyqxmd.com/read/29670547/medications-used-for-cognitive-enhancement-in-patients-with-schizophrenia-bipolar-disorder-alzheimer-s-disease-and-parkinson-s-disease
#17
REVIEW
Wen-Yu Hsu, Hsien-Yuan Lane, Chieh-Hsin Lin
Background/aims: Cognitive impairment, which frequently occurs in patients with schizophrenia, bipolar disorder, Alzheimer's disease, and Parkinson's disease, has a significant impact on the daily lives of both patients and their family. Furthermore, since the medications used for cognitive enhancement have limited efficacy, the issue of cognitive enhancement still remains a clinically unsolved challenge. Sampling and methods: We reviewed the clinical studies (published between 2007 and 2017) that focused on the efficacy of medications used for enhancing cognition in patients with schizophrenia, bipolar disorder, Alzheimer's disease, and Parkinson's disease...
2018: Frontiers in Psychiatry
https://www.readbyqxmd.com/read/29642738/rats-and-rabbits-as-pharmacokinetic-screening-tools-for-long-acting-intramuscular-depots-case-study-with-paliperidone-palmitate-suspension
#18
Harilal Patel, Prakash Patel, Nirav Modi, Pinakin Patel, Yogesh Wagh, Alex George, Nirmal Desai, Nuggehally R Srinivas
1. Development of prodrug of paliperidone (9-hydroxyrisperidone) long-acting intramuscular injection has enabled delivery over 4-week time period with improved compliance. 2. Key aim of work was to establish a reliable preclinical model which may potentially serve as a screening tool for judging the pharmacokinetics of paliperidone formulation(s) prior to human clinical work. 3. Sparse sampling composite study was used in rats, (Wistar/Sprague-Dawley (n = 10)). A serial blood sampling study design was used in rabbits (n = 4)...
April 12, 2018: Xenobiotica; the Fate of Foreign Compounds in Biological Systems
https://www.readbyqxmd.com/read/29606876/factors-related-to-improvement-of-symptoms-function-and-caregiver-burden-in-chinese-patients-with-schizophrenia-after-switching-to-paliperidone-palmitate-once-monthly-from-oral-antipsychotics
#19
Nan Li, Yu Feng, Huafei Lu, Shang Li Cai, Jianmin Zhuo, Tianmei Si, Lili Zhang
Background: Paliperidone palmitate once-monthly (PP1M) demonstrated symptomatic and functional remission in patients with schizophrenia. This post hoc analysis aimed to identify factors associated with improved clinical outcomes in patients switching to PP1M (75-150 mg eq.). Methods: The improved patient outcomes were observed as Positive and Negative Symptom Scale (PANSS, symptoms) score <70:66.7% (407/610), Personal and Social Performance (PSP, function) score >70:34...
2018: Neuropsychiatric Disease and Treatment
https://www.readbyqxmd.com/read/29574303/prevalence-and-correlates-of-antipsychotic-polypharmacy-in-hong-kong
#20
Stephanie Lock Man Lung, Ho Ming Edwin Lee, Yu Hai Eric Chen, Kit Wa Sherry Chan, Wing Chung Chang, Lai Ming Christy Hui
BACKGROUND: Antipsychotic polypharmacy (APP) remains a common practice despite inconclusive empirical evidence of additional efficacy and potential exacerbation of side effects. Previous studies suggest APP rate is notably high in East Asia. This paper aims to investigate the prevalence and correlates of APP in Hong Kong. METHOD: This was a cross-sectional study of 728 patients with psychosis. The demographics and clinical information, including age, gender, diagnosis, hospitalization history, and medication were collected...
March 10, 2018: Asian Journal of Psychiatry
keyword
keyword
32835
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"